摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
$ |1 [2 R1 H7 I& N% U 关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
" d- ~: f% p& s& z, P9 ? / w4 k- g+ t& `/ n* m$ R5 @
作者：来自澳大利亚* b, [7 ~! E8 I* C' O2 z; C4 R
来源：Haematologica. 2011.8.9.
B, D& }# n& g# V l$ x' FDear Group,
. H: }( K3 d/ @% J0 L
1 W) |" ?2 G' E5 r' v H, l/ ESome of you are on Dasatinib (Sprycel) and we wish to give news on all CML8 G' C/ y! u) m3 N# x) U
therapies. Here is a report from Australia on 3 patients who went off Sprycel
V% `: R* e: g2 A2 z* xafter stable molecular response (PCRU). 1 patient relapsed but 2/3 patients: R, N5 S! R2 J" D
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
/ J( L8 E1 U; L7 Q* N/ bdoes spike up the immune system so I hope more reports come out on this issue.+ J) _/ J1 D7 v
) u) E3 b+ z! E) [
The remarkable news about Sprycel cessation is that all 3 patients had failed
; y0 m2 X) J2 t6 D" K4 oGleevec and Sprycel was their second TKI so they had resistant disease. This is
, D$ T, K4 c9 c" Cdifferent from the stopping Gleevec trial in France which only targets patients
6 g/ n+ O; p: Z" _/ S: C( mwho have done well on Gleevec.
/ x6 `2 Y, d8 q$ L! j u2 s R- o. K* ^+ u! E4 F3 @1 I
Hopefully, the doctors will report on a larger study and long-term to see if the& S& W" M. D9 o. P
response off Sprycel is sustained.
3 Q# v8 E2 j4 W8 J
: `6 E) _5 _3 aBest Wishes,
) }; h& e5 ]2 O% X# w$ yAnjana O' j D9 ^7 v ?$ y# C
9 a! x i1 `+ D) N% o$ ~3 C `2 T8 E
) \9 @) A5 k$ J
$ j m" j+ ]5 w. K" _7 d5 [3 C+ y
Haematologica. 2011 Aug 9. [Epub ahead of print]6 C; Q& V5 c& ~# j7 e& n' i
Durable complete molecular remission of chronic myeloid leukemia following
4 h* I& z& t. j' C, Z3 Ndasatinib cessation, despite adverse disease features.
( E& V, m) q( F8 c; O- H% N2 sRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.5 u) \/ U5 s7 E7 |" F
Source* y9 @' P+ I% M
Adelaide, Australia;/ Q4 M8 Y9 H. ]. Z% _
3 L2 J2 ]* k1 T' ?) E8 R
Abstract- Y% @" V* I5 v6 P$ e
Patients with chronic myeloid leukemia, treated with imatinib, who have a0 i( q# n; S3 `; N4 x2 a
durable complete molecular response might remain in CMR after stopping
3 O& R: I8 Y+ i2 T5 p* wtreatment. Previous reports of patients stopping treatment in complete molecular
- h; z8 x: ]) I8 |. h" W( n+ e) yresponse have included only patients with a good response to imatinib. We! E! N0 n$ s5 O1 F! f0 p1 Z: p7 ]
describe three patients with stable complete molecular response on dasatinib
* Q# k! _) ~( x1 v% \* _treatment following imatinib failure. Two of the three patients remain in
" u @* u7 i6 r9 Ecomplete molecular response more than 12 months after stopping dasatinib. In- P* d' [( S0 ^' O5 J) v- V
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
' s& G; R5 K0 T$ L2 Pshow that the leukemic clone remains detectable, as we have previously shown in
7 k) T& f/ V) X! |' Ximatinib-treated patients. Dasatinib-associated immunological phenomena, such as
3 j8 q+ A! k! V7 Y8 _the emergence of clonal T cell populations, were observed both in one patient
: {. f! d/ f- i% bwho relapsed and in one patient in remission. Our results suggest that the
" `2 U, A1 g+ @% J/ {7 ]# `characteristics of complete molecular response on dasatinib treatment may be
" G r2 `. s3 h$ zsimilar to that achieved with imatinib, at least in patients with adverse/ J. ?) t6 w* t8 l: U
disease features.! u. k. L3 L- z+ x4 t3 P
|
显身卡
